Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.775
-0.075 (-4.05%)
Aug 28, 2026, 1:43 PM EDT - Market open
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
77.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GANX News
- 3 days ago - Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 16 days ago - Gain Therapeutics Earnings release: Q2 2026 - Filings
- 16 days ago - Gain Therapeutics Quarterly report: Q2 2026 - Filings
- 17 days ago - Gain Therapeutics reports Q2 EPS (11c), consensus (15c) - TheFly
- 25 days ago - Gain Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics receives FDA clearance of GT-02287 IND application - TheFly
- 2 months ago - Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease - GlobeNewsWire